We studied the outcome of allogeneic transplants in 135 patients who received selected BM and/or PBSC CD34 ؉ cells from HLA haplo-identical related donors. Donor engraftment was achieved in 108 of 128 evaluable transplants. Engraftment failure occurred more often in nonmalignant than in malignant diseases (10 of 25 vs 17 of 103, P ‫؍‬ 0.010). The CD34 ؉ cell dose was associated with the speed of neutrophil and platelet recovery, but the cell source was not. Acute GVHD (уgrade II) developed in 21.0 ؎ 3.7%. Chronic GVHD occurred more frequently in malignancies than in non-malignancies (44.1 ؎ 7.6% vs 0.0%, P ‫؍‬ 0.0075), and more in PBSC recipients than in BM recipients (53.6 ؎ 9.4% vs 17.4 ؎ 9.3%, P ‫؍‬ 0.0054). Relapse rate was higher in high risk patients than in standard risk patients (78.7 ؎ 7.1% vs 22.1 ؎ 10.0%, P ‫؍‬ 0.0001). Probabilities of disease-free survival (DFS) were 14.2 ؎ 3.5% in malignancies and 25.7 ؎ 9.2% in non-malignancies. Probabilities of DFS in standard and high risk patients were 39.4 ؎ 9.2% and 5.7 ؎ 2.8% (P ‫؍‬ 0.0001). A high incidence of graft failure, infection and relapse was observed and resulted in high mortality. Bone Marrow Transplantation (2000) 26, 1281-1290.
registries has facilitated identification of suitable donors for most of the patients. However, many patients lose an opportunity for unrelated transplantation because of the long interval needed for coordination in bone marrow banks or because of an insufficient number of nucleated cells in cord blood units.
Hematopoietic stem and progenitor cells are considered to be contained within the CD34 ϩ cell population of the bone marrow (BM) and the peripheral blood (PB). 1, 2 Early studies in human and animal models showed that autologous and allogeneic transplantation of selected CD34 ϩ cells could reconstitute hematopoiesis. [3] [4] [5] Since then many groups have reported sustained engraftment using BM or PB CD34
ϩ cells from HLA-matched or mismatched donors, and from related or unrelated donors, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] but it is still unknown which cell source is better and how many cells are necessary to achieve rapid and durable engraftment.
Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation (HSCT), especially from HLA-mismatched related or unrelated donors. T cell depletion (TCD) from the graft is an effective method to prevent severe GVHD, but TCD is often associated with a high incidence of graft failure, infection and leukemia relapse. [20] [21] [22] [23] [24] [25] Allogeneic CD34 ϩ cell transplantation has been used as a new method of TCD, but the results of early studies in HLA-matched HSCT were not constant in the rate of severe GVHD. 6, [8] [9] [10] 14, 16, 18 It is still unknown to what extent HLA disparity between the donor and the recipient is feasible by using this method. 7, 13, 15 We and several other groups have reported a rapid hematopoietic recovery without significant acute GVHD, but to date no studies have reported a long-term survival or leukemia relapse rate after CD34 ϩ -selected HSCT. Here we report the results of a national survey on CD34
ϩ HSCT in Japan with a special focus on the source and the dose of transplanted cells.
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Materials and methods
Patients
One hundred and thirty-five patients, 79 male and 56 female, received allogeneic transplants using BM and/or PB CD34 ϩ cells at 36 institutions in Japan between September 1993 and September 1998, and were observed until 1 June 1999. The ages of the patients ranged from Ͻ1 to 44 years with a median of 8 years, and the weights from 5.4 to 88.0 kg with a median of 23.7 kg. The diagnosis included acute lymphoblastic leukemia (ALL) (n ϭ 46), acute myelogenous leukemia (AML) (n ϭ 32), chronic myelocytic leukemia (CML) (n ϭ 13), myelodysplastic syndrome (MDS) (n ϭ 8), neuroblastoma (n 6), non-Hodgkin's lymphoma (n ϭ 1), severe aplastic anemia (n ϭ 11), Fanconi's anemia (n ϭ 5), inborn errors of metabolism (n ϭ 2), severe combined immunodeficiency (n ϭ 6), Wiskott-Aldrich syndrome (n ϭ 1), hemophagocytic syndrome (n ϭ 3) and chronic active EBV infection (n ϭ 1). Patients with hematological or other malignancies were divided into standard and high risk groups according to the stages. There were 29 standard risk patients who were in first or second remissions of acute leukemia, first chronic phase of CML or refractory anemia of MDS, and 81 high risk patients who were in more advanced conditions. All patients were considered to be eligible for allogeneic transplantation but lacked related or unrelated histocompatible donors.
Informed consent
All donors and patients or their guardians signed informed consent forms approved by the Institutional Review Board of each institute.
Donors
One hundred and thirty-five donors were HLA haplo-identical family members; 28 were zero to one mismatched, 64 were two mismatched and 43 were three mismatched. Second or third transplants were performed from the same or different donors in 10 patients because of graft failure (eight early, one late) or relapse of leukemia (one).
Bone marrow (BM) cells were harvested from 61 donors, and peripheral blood stem cells (PBSC) were collected from 97 donors who were given human granulocyte colonystimulating factor (G-CSF, filgrastim; Kirin, lenograstim; Chugai, nartograstim; Kyowa, Tokyo, Japan) 5-10 g/kg/day for 4 to 5 days.
Thirty-eight transplants were done using BM only, 74 PBSC only and 23 both BM and PB. Patient characteristics in each transplant group are shown in Table 1 . Sex, diagnosis and risk at transplant in patients with malignancy distributed equally between the three groups. Younger children with lighter weights tended to receive either BM or PB alone, and older children or adults with heavier weights received PB with or without BM more frequently as a source of CD34 ϩ cells (P Ͻ 0.02). ATG was used more frequently in BM (18/38) or BM ϩ PB (12/23) than in PB recipients (17/74) (P Ͻ 0.01).
Positive selection and infusion of CD34
ϩ cells CD34 ϩ cells were selected using the Isolex system (Nexell Healthcare Corp, Irvine, CA, USA) according to the manufacturer's suggestions. Briefly, mononuclear cells from BM or PB were incubated with anti-CD34 monoclonal antibody (MoAb, 9C5). The cells were washed three times with RPMI/HSA (human serum albumin) and then resuspended in RPMI/HSA containing 5% human ␥-globulin. The CD34 ϩ cell suspension was incubated with sheep antimouse IgG 1 antibody coated immunomagnetic beads to allow rosette formation. Rosetted CD34 ϩ cells were separated by exposure to the magnet and the linkage between beads and the CD34 ϩ cells was cleaved by chymopapain in earlier cases and by peptide in later cases.
Selected CD34 ϩ cells were infused with or without cryopreservation.
Transplantation procedures
Transplant centers used their own protocols for conditioning and prophylaxis of GVHD. Conditioning regimens were intensified, and varied from center to center and from patient to patient. Total body irradiation (TBI) containing conditioning was used in 104 of 110 transplants in patients with malignancy, and some form of irradiation was applied in 18 of 25 transplants in patients with non-malignant diseases other than myelosuppressive and/or immuno-suppressive agents. Anti-thymocyte globulin (ATG, PasteurMerieux, Lyon, France) was used as a part of the conditioning in 47 transplants (35 malignant and 12 non-malignant).
In 105 transplants, patients received post-transplant GVHD prophylaxis with cyclosporine, tacrolimus (FK-506), methotrexate, and steroid, either alone or in combination. In 30 transplants, CD34 ϩ cell selection was the only measure of GVHD prophylaxis. Acute and chronic GVHD was diagnosed and graded according to standard criteria.
G-CSF was administered to all patients after transplantation. Donor engraftment and chimerism were evaluated by cytogenetic and DNA analysis of one or more genetic differences between the donor and the recipient (sex, HLA and variable number of tandem repeats (VNTR)). No detection of donor cells within 30 days after HSCT was defined as early engraftment failure, and transient hematological recovery followed by disappearance of donor cells after 30 days post HSCT as late engraftment failure.
Data collection and statistical analysis
Data on outcomes of transplantation were collected at intervals during follow-up for 135 patients and 135 donors from 36 participating centers. All data were checked and confirmed by contact between one or more of the investigators and the staff at the transplant centers.
The first day of CD34 ϩ cell infusion was defined as day 0. Neutrophil engraftment was defined as the first of 3 consecutive days to achieve an absolute neutrophil count over 0.5 ϫ 10 9 /l. Platelet engraftment was defined as the first day to maintain an untransfused platelet count over 50 ϫ 10 9 /l. Engraftment, acute GVHD and chronic GVHD, relapse, (77) 12 (52) The differences were significant ( a P Ͻ0.001, and b P Ͻ0.01).
disease-free survival (DFS) were evaluated only in the first transplants. Chronic GVHD was evaluated only in patients at risk who survived with donor engraftment and without recurrence of the original disease longer than 60 days after HSCT.
Comparison of variables related to the patients, the underlying diseases, and the transplantation procedures between three groups was done using the chi-square test for categorical variables and the Mann-Whitney test for continuous variables. The probability of DFS was estimated by the Kaplan-Meier method. The log-rank test was used for univariate comparisons. Cumulative incidence curves were used to calculate the probability of neutrophil and platelet engraftment, acute and chronic GVHD, and relapse. The association of the sources of transplanted cells, the transplanted CD34 ϩ cell doses, the type and the risk of the underlying diseases and other variables with the transplant outcomes were evaluated in multivariate analyses, with the use of Cox proportional hazards regression model to adjust the differences.
The data were analyzed using SPSS software for Windows (SPSS Inc., Chicago, IL, USA).
Results
Donors
Donors who were given G-CSF for mobilization of PBSC tolerated this procedure, although some suffered from mild Bone Marrow Transplantation to moderate bone pain, headache and fatigue. No serious complication occurred either in PBSC or in BM donors.
Selection of CD34
ϩ cells CD34 ϩ cell selection was performed in 61 BM and 141 PBSC grafts. The numbers of CD34 ϩ and CD3 ϩ cells are shown in Tables 2 and 3 
-test).
The average numbers of CD34 ϩ cells infused were 3.2 Ϯ 2.3 (range, 0.3-9.1) ϫ 10 6 /kg for BM graft recipients, 5.5 Ϯ 3.6 (0.6-22.8) ϫ 10 6 /kg in PBSC recipients and 4.9 Ϯ 7.1 (0.9-36.2) ϫ 10 6 /kg for BM and PBSC recipients. The difference between BM recipients and PB recipients was significant (P Ͻ 0.001).
The average number of CD34 ϩ cells in grafts before and after the procedure was 1.0 Ϯ 1.3 ϫ 10 9 and 11.6 Ϯ 18.6 ϫ 10 5 for BM (n ϭ 47), and 9.7 Ϯ 10.0 ϫ 10 9 and 12.2 Ϯ 13.7 ϫ 10 5 for PBSC (n ϭ 101). The average CD3 ϩ cell depletion was 3.3 (median 3.2, range 2.0-5.2) log for BM and 4.0 (median 3.9, range 2.6-5.2) log for PBSC. Data are expressed as the mean and the range except for CD34 ϩ cell recovery. a The difference was significant (P Ͻ 0.05). /kg for BM ϩ PB recipients, and the differences were not significant.
Engraftment
Engraftment of donor CD34
ϩ cells was evaluable in 128 transplants. Seven transplants could not be evaluated because of early death or persistence of leukemia. Primary engraftment failure occurred in 20 and late in seven transplants. Ten of 25 transplants in non-malignant patients and 13 of 103 transplants in malignant patients failed to engraft, and the difference was significant (P ϭ 0.010, Pearson's 2 test). Three of 36 BMT, 16 of 70 PBSCT and eight of 22 BM ϩ PB SCT failed engraftment, but the differences were not significant. Nine patients with early or late engraftment failure received the second or third transplantation, and six patients finally achieved complete donor engraftment.
ATG administration as a part of conditioning did not affect engraftment rate: 6/44 in the ATG group and 14/84 in the non-ATG group.
The lowest dose of CD34 ϩ cells in engrafted patients was 0.3 ϫ 10 6 /kg in BM, 1.2 ϫ 10 6 /kg in the PB and 0.9 ϫ 10 6 /kg in the BM ϩ PB recipients, respectively. Incidences of graft failure were 18.2% in those given less than 2 ϫ 10 6 /kg of CD34 ϩ cells, 18.0% in those between 2 and 4 ϫ 10 6 /kg and 15.2% in those given more than 4 ϫ 10 6 /kg but the differences were not significant.
The time to reach an absolute neutrophil count (ANC) of 0.5 ϫ 10 9 /l ranged from 8 to 79 days with medians of 13 days by Kaplan-Meier's estimate for all patients who underwent transplantation, and 12 days for those in whom neutrophil engraftment occurred. The medians were 14 days for BM CD34 ϩ cell recipients, 12 days for PBSC CD34 ϩ cell recipients and 14 days for BM ϩ PBSC CD34 ϩ cell recipients (Figure 1a ). The differences between transplanted cell sources were not significant. The medians were 12 days for patients who were given CD34 ϩ cells more than 4 ϫ 10 6 /kg, and 14 days for those given less; the difference was significant (P ϭ 0.0336, Figure 2a) . The medians did not differ according to the type of disease: 13 days in patients with malignancies and 12 days in those with non-malignant diseases. The time to reach a platelet count of 50 ϫ 10 9 /l ranged from 10 to 353 days with a median of 68 days for all patients and 34 days for patients who reached this end point. The medians were 60 days for BM CD34 ϩ cell recipients, 72 days for PBSC CD34 ϩ cell recipients and 353 days for BM ϩ PBSC CD34 ϩ cell recipients ( Figure  1b) . The differences between cell sources were not significant. The medians were 58 days for patients who were given CD34 ϩ cells more than 4 ϫ 10 6 /kg, and 80 days for patients given less; the difference was significant (P ϭ 0.0437, Figure 2b) .
In the multivariate analysis, only transplanted CD34 ϩ cell number/kg was significant both for neutrophil (P ϭ 0.0252) and for platelet engraftment (P ϭ 0.0212) ( Table  4) .
GVHD
Information on acute GVHD was available for 118 transplants; grade 0 in 43, grade I in 46, grade II in 19, grade III in 10 and grade IV in 0. The cumulative incidence of acute GVHD of grade II or more was 21.3 Ϯ 3.7% at day 60 post transplantation. The incidence was 10.4 Ϯ 4.4% in 47 patients who were given ATG as part of conditioning whereas it was 27.1 Ϯ 5.0% in 71 patients without ATG (P ϭ 0.0288) (Figure 3 ). The severity of acute GVHD did not correlate with the patient's age, the extent of HLA disparity, the number of transfused CD3
ϩ cells/kg, presence or absence of postBone Marrow Transplantation transplant GVHD prophylaxis, the source or the number of CD34 ϩ cells/kg or the type of disease. Chronic GVHD, mostly limited, occurred in 20 of 57 patients at risk: 20 of 44 patients with malignancies and none of 13 patients with non-malignancies (44.1 Ϯ 7.6% vs 0.0%, P ϭ 0.0075, Figure 4a ). The incidence was higher in 28 PB recipients (53.6 Ϯ 9.4%) than in 20 BM (17.4 Ϯ 9.3%) or nine BM ϩ PB recipients (11.1 Ϯ 10.5%) (P ϭ 0.0047, Figure 4b ). ATG recipients had lower incidence of chronic GVHD than ATG non-recipients (13.0 Ϯ 7.1% vs 51.8 Ϯ 9.0%, P ϭ 0.0009) (Figure 4c ). Onset was earlier in PB recipients (median 90, range 60 to 150 days) and in ATG non-recipients (median 90, range 60 to 132 days) than in BM recipients (median 122, range 120 to 150 days) or ATG-recipients (median 125, range 120 to 150 days).
The number of mismatched HLA antigens, the patients' age, transfused CD3 ϩ or CD34 ϩ cell dose/kg did not correlate with the incidence of chronic GVHD (data not shown).
In multivariate analysis, acute GVHD уII was associated with absence of ATG (P ϭ 0.0131), and the cell source (PB only vs others, P ϭ 0.0377) ( Table 4) . The Cox regression model was not applicable in the comparison between malignant and non-malignant disease because none of one group developed chronic GVHD.
Relapse
Relapse was identified in a range of 13 to 440 days with a median of 86 days after transplantation in 38 patients (11 of 46 with ALL, 13 of 32 with AML, six of 13 with CML, two of eight with MDS, five of six with neuroblastoma and one of three with HPS). Probabilities of relapse in standard risk patients and high risk patients were 22.1 Ϯ 10.0% and 78.7 Ϯ 7.1%, and the difference was highly significant (P ϭ 0.0001, Figure 5 ).
In the multivariate analysis, relapse was associated with the risk (P ϭ 0.0006, Table 4 ).
Survival
Thirty-seven of 135 patients are surviving after the first SCT with a median follow-up of 34 months after transplantation, and 25 are disease-free survivors. Three of 10 patients who received the second or third transplant because of graft failure (nine) or leukemia relapse (one) finally became disease-free survivors, but these 10 patients were considered as failure at the time of graft failure or relapse in the following analyses.
Probabilities of engrafted and disease-free survival (DFS) were 14.2 Ϯ 3.5% at 67 months for patients with malignancies and 25.7 Ϯ 9.2% at 53 months for patients with non-malignancies; the difference was not significant (Figure 6a ). Probabilities of DFS were 39.4 Ϯ 9.2% for standard risk patients and 5.7 Ϯ 2.8% for high risk patients; the difference was highly significant (P ϭ 0.0001, Figure  6b ). DFS of children who were 5 years or younger was 27.9 Ϯ 6.3% and that of older patients was 8.6 Ϯ 3.4% (P ϭ 0.0232) (Figure 6c ). DFS rates were not different according to the source or number of transplanted CD34 ϩ or CD3 ϩ cells (data not shown). The DFS rate of the malignant patients who were given ATG was superior until 5 months post SCT, but became inferior after 5 months to that of those who were not given ATG, although the difference was not significant (Figure 6d) .
In multivariate analysis, DFS was associated with the risk in malignant patients (P ϭ 0.0001).
Causes of death
Ninety-eight patients were reported to be dead 0 to 32 months after the first SCT. Causes of death were infection in 37 patients (38%; CMV 8, EBV 3, HHV-6 2, bacterial 10, fungal 10, unknown 4), relapse in 29 (30%), GVHD in 5 (5%), veno-occlusive disease in 5 (5%), and other transplant-related mortality in 22 (22%).
Discussion
Our current study included data on more than 100 patients who were given CD34 ϩ cells selected from the bone marrow and/or the blood of HLA-haploidentical related donors. The relatively large number of patients and the variety of the transplanted cell sources and cell numbers enabled statistical comparisons.
The Isolex system was used to isolate CD34 ϩ cells from the BM and the PB in all cases. The total number of mononuclear and CD34 ϩ cells in the PB was higher than those in the BM before CD34 ϩ cell selection. The recovery rate of CD34 ϩ cells after selection was higher in PB than in BM, probably due to higher expression of CD34 antigens on the blood stem and progenitor cells than on the marrow stem and progenitor cells. The median purity of CD34 ϩ cells in the final grafts in our study was around 90% and was higher than those obtained with the Ceprate SC system (CellPro, Seattle, WA, USA) (50-70%) reported by several groups. 6, 8, 9 A sufficient number of CD34 ϩ cells was obtained from BM alone in pediatric patients whose parental donors were much heavier than the recipients. However, it was difficult to achieve enough CD34 ϩ cells from BM alone for older children or heavy adults and therefore PB with or without BM was used as a source of transplanted CD34 ϩ cells in many institutes.
Allogeneic PBSCT has recently been performed because of faster engraftment, but it is not fully understood if there is a qualitative difference between BM and PB stem/progenitor cells. [26] [27] [28] [29] [30] [31] Our study made it possible to compare the hematopoietic ability of CD34 ϩ cells from two sources since they were highly purified and the influence of other cells was minimal.
Analysis between the two cell sources did not show any significant difference in the speed or the rate of engraftment. This may indicate that the BM CD34 ϩ and the PB CD34 ϩ cells have equivalent potency of engraftment ability.
The number of transplanted CD34 ϩ cells, however, was associated with the speed of neutrophil and platelet engraftment. A greater number of CD34 ϩ cells induced a faster cell recovery and a higher final platelet engraftment rate. This dose dependency in the speed of engraftment was similar to Miflin's observation in unmanipulated PBSCT, in which higher doses of CD34 ϩ cells (у4 ϫ 10 6 /kg) gave faster neutrophil and platelet engraftment. 27 Russell et al 26 presumed the minimum number of CD34 ϩ cells to be 2 to 3 ϫ 10 6 /kg in unmanipulated allogeneic PBSCT. Although we could not identify the minimum number of CD34 ϩ cells required for engraftment of purified CD34 ϩ cells, 85% of Bone Marrow Transplantation those who received more than 5 million CD34 ϩ cells/kg and 82% of those who received more than 2 million/kg engrafted.
Engraftment failure occurred more frequently in nonmalignant disease than in malignant disease. A similar tendency has been reported in unrelated cord blood transplantation by Rubinstein et al. 32 Donor hematopoietic engraftment is considered to be determined by the immunological balance between the donor graft and the residual host immunity which has survived immunosuppressive conditioning. Host immunity often can not be sufficiently eradicated in non-malignant patients and therefore can reject the donor graft with qualitative or quantitative defects in T lymphocytes.
A second or third transplant was performed with repeated conditioning in nine patients who had rejected the first graft, and resulted in final engraftment in six patients. This suggests the possibility that further intensification of conditioning can reduce the incidence of graft failure. The use of ATG in conditioning, however, did not contribute to higher engraftment.
Aversa et al 15 /kg of PB ϩ BM CD34 ϩ cells after intensive chemo-radiotherapy, and all of 43 patients achieved full donor-type engraftment without late rejection. Our results agree with their hypothesis that CD34 ϩ cell number is important for high engraftment rate.
The Isolex system achieved as much as 2 to 5 log T cell depletion while other classical TCD methods were reported to remove T cells up to 2 logs in most instances. [20] [21] [22] [23] 33 Thus, a majority of patients received T cells in the range of 10 3 to 10 4 /kg, a range which had been believed not to cause clinically significant acute GVHD both in HLAmatched and mismatched BMT. This high level of TCD resulted in a very low incidence of severe acute GVHD in HLA-mismatched recipients, and effects of the number of mismatched HLA antigens on the severity of acute GVHD did not exist probably because of absence or insufficient number of T cells. Aversa et al 15 reported complete prevention of acute GVHD in TCD HSCT recipients who were given 4 to 8 ϫ 10 4 CD3 ϩ /kg cells from mismatched related donors. Since severe acute GVHD was often observed in CD34 ϩ HSCT recipients who were given more T cells in the range of 10 6 /kg even from HLA-matched sibling donors, 6 ,9 CD3 ϩ cell dose should be maintained at less than 1 ϫ 10 6 /kg in order to prevent severe acute GVHD. The source of stem or T cells did not affect the occurrence or severity of acute GVHD in our study as reported by Cornelissen et al. 16 Unmanipulated allogeneic PBSCT has been reported to be associated with a high incidence of chronic GVHD, 28, 31, 34 but it is not known if this is due to infusion of a much higher number of T cells or due to an altered balance of Th1/Th2 in the graft. The incidence of chronic GVHD was increased in our PB CD34 ϩ cell recipients. Cornelissen et al 16 also reported a higher incidence of chronic GVHD in PB TCD recipients than in BM TCD ϩ cells in BM. The use of ATG before HSCT significantly reduced the incidence of both acute and chronic GVHD. Exposure of donor T and/or stem cells to ATG just after transplantation may have not only short but also long-term effects on immune recovery, which may have resulted in increased incidence of infection and relapse.
A high incidence of infection was observed in our patients and in other series of CD34 ϩ HSCT as already reported in the classical TCD transplantation. 24, 25, 35, 36 Delayed immune reconstitution in the first 6 months following CD34 ϩ cell transplantation was reported and would explain the increased incidence of these post-transplant events. 37 Additional immunotherapy such as donor leukocyte transfusion (DLT) will be necessary to prevent infection and relapse, but DLT from HLA-mismatched donors can often cause fatal GVHD. 15 We have demonstrated that allogeneic transplantation of purified BM and/or PB CD34 ϩ cells from HLA haploidentical donors can reconstitute durable hematopoiesis. The longest survivor in this series is 69 months post HSCT, and complete trilineage hematopoiesis has been maintained in this patient as well as in other long-term survivors. This evidence confirms the hypothesis that long-term repopulating stem cells reside in the CD34 ϩ HSCT recipients included in this study while they were present in normal individuals and in the recipients of unmanipulated BM, and that CD34 Ϫ Lin Ϫ stem cells play an important role in lymphopoiesis (unpublished observation). This may explain the profound and long-lasting immunodeficiency due to lymphopenia both in allogeneic and in autologous CD34 ϩ HSCT recipients. Addition of CD34 Ϫ Lin Ϫ stem cells to CD34 ϩ cells may enhance recovery of lymphocytes and should be explored as a possible solution for defects in immunity after transplantation.
Unrelated BMT, unrelated PBSCT, and unrelated cord blood transplants are currently performed as alternative transplants to HLA-matched sibling transplantation other than CD34 ϩ -related HSCT in patients with potentially fatal hematological diseases who lack HLA-identical sibling donors. Comparisons should be made between these different types of transplantation to clarify characteristics of each treatment and to determine any measurable differences among them.
We conclude that the selected BM and/or PB CD34 ϩ cells from HLA haplo-identical related donors can reconstitute long-lasting hematopoiesis in man. The speed of neu-trophil and platelet recovery depends on the CD34 ϩ cell dose, but not on the CD34 ϩ cell source. Three to four logs of reduction of transfused CD3 ϩ cells efficiently prevented severe acute GVHD in HLA-mismatched transplantation, but a substantial proportion of long-term surviving recipients developed chronic GVHD. Chronic GVHD occurred more frequently in PB CD34 ϩ recipients than in BM or BM ϩ PB recipients, but CD3 ϩ cell dose was not associated with chronic GVHD. The use of ATG in conditioning reduced acute and chronic GVHD, but the engraftment or disease-free survival rates were not influenced by the use of ATG. Relapse rate of leukemia or other malignancies was significantly higher in high risk patients than in standard risk patients. Considerable increases in graft failure, infection, and relapse of malignancies were limitations in this type of transplantation.
